Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor.

Gagnon AW, Aiyar N, Elshourbagy NA

Cellular signalling1 Mar 1994Cited by 18 (Europe PMC)

PMID7917790DOI10.1016/0898-6568(94)90037-xPepBankPUB-07917790

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In COS cells expressing a human liver VIP receptor chimera, 125I-VIP bound a single site with a Kd of 9.2 nM.
In plain wordsIn lab-grown cells carrying a human liver VIP receptor, VIP bound to one site with a Kd of 9.2 nM.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicable125I-VIP binding affinity (Kd)
Study
n: not reported in source
COS cells transfected with the human VIP receptor chimera
Outcome group
Receptor activity and mechanism · Liver
Studied dose
Dose not stated
Measurements
Kd
9.2 nM
125I-VIP, COS cells with human VIP receptor chimera
Source sentences
Summary
COS cells transiently transfected with this human VIP receptor chimera, express a single binding site for 125I-VIP with a Kd of 9.2 +/- 2 nM.
Report a problemFND-0791779001
02LabIn vitro (cells)Activity measurement
In COS cells expressing the human VIP receptor chimera, VIP and PACAP displaced 125I-VIP with equal potency, more than helodermin, PHM and secretin.
In plain wordsIn lab-grown cells carrying a human liver VIP receptor, VIP and PACAP bound best, ahead of helodermin, PHM and secretin.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableDisplacement of 125I-VIP by related peptides
Study
n: not reported in source
COS cells transfected with the human VIP receptor chimera
Outcome group
Receptor activity and mechanism · Liver
Studied dose
Dose not stated
Source sentences
Summary
Related peptides displace 125I-VIP with a relative potency of VIP = PACAP > helodermin >> PHM > secretin, which is similar to the binding profile seen in human tissues.
1 context sentence(design, population, supporting numbers)
Summary · context
COS cells transiently transfected with this human VIP receptor chimera, express a single binding site for 125I-VIP with a Kd of 9.2 +/- 2 nM.
Report a problemFND-0791779002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.